EUVIMEDEUVIMED entdecken
Crossref

Long‐term effectiveness and persistence rate of ustekinumab dose intensification in a South East Asian inflammatory bowel disease center

Chong-Teik Lim iD, Shu-Wen Tay, Sakktivel Elangovan, Wan-Chee Ong, Gek-Hsiang Lim, Ennaliza Salazar iD, Webber P W Chan, Malcolm T K Tan

Journal of Gastroenterology and Hepatology · 2024

DOI: 10.1111/jgh.16562 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Chong-Teik Lim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore. Hauptthemen laut MEDLINE: Ustekinumab, Crohn Disease, Colitis, Ulcerative. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Ustekinumab (UST) is an effective biologic for treatment of inflammatory bowel disease (IBD). However, some patients treated with UST have suboptimal clinical response with standard dosing. The aims of this study were to determine the effectiveness of UST dose intensification (DI), identify factors associated with DI, cumulative incidence of DI and persistence of UST among treated patients.

Methods

Clinical data of patients with Crohn's disease (CD) and ulcerative colitis (UC) who received UST from September 2017 to October 2022 in Singapore General Hospital were collected. Primary outcome was defined as achieving corticosteroid‐free clinical remission, biochemical remission, endoscopic healing and/or transmural healing (CD). Statistical analysis was performed to identify factors, which are predictive of UST DI and effectiveness of UST DI.

Results

Forty‐two patients (34 CD and 8 UC) underwent UST DI to either 6‐weekly ( n = 19, 45.2%) or 4‐weekly ( n = 23, 35.9%) and the median time to intensification was 31.1 weeks (17.8–65.7). Presence of perianal disease in CD (HR 4.9; 1.47–16.4) was associated with DI. After DI, 16 (38%) patients achieved primary outcome by week 52. The overall drug persistence rates at 1 year and 2 years were 75.7% (95% CI 62.9–84.6) and 63.5% (95% CI 49.9–74.3), respectively.

Conclusion

Two third of IBD patients underwent DI while on UST treatment and the median time to DI was about 6 months after induction. CD patients with perianal disease is more likely to undergo DI. More than one third of dose‐intensified patients achieved remission by week 52.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabCrohn DiseaseColitis, UlcerativeHumansFemaleMaleAdultTreatment OutcomeMiddle AgedTime FactorsSingaporeRemission InductionInflammatory Bowel DiseasesEast Asian People

Stichwörter der Autor:innen

dose intensificationinflammatory bowel diseaseustekinumab

Substanzen

Ustekinumab

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore.
  • Ministry of Health Holdings, Singapore.
  • Department of Pharmacy, Singapore General Hospital, Singapore.
  • Health Services Research Unit, Singapore General Hospital, Singapore.

ORCID-Profile: Chong-Teik Lim, Ennaliza Salazar

Zitieren

APA

Lim, C. T., Tay, S. W., Elangovan, S., Ong, W. C., Lim, G. H., Salazar, E., Chan, W. P. W., & Tan, M. T. K. (2024). Long‐term effectiveness and persistence rate of ustekinumab dose intensification in a South East Asian inflammatory bowel disease center. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16562

Vancouver

Lim CT, Tay SW, Elangovan S, Ong WC, Lim GH, Salazar E, et al. Long‐term effectiveness and persistence rate of ustekinumab dose intensification in a South East Asian inflammatory bowel disease center. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16562

BibTeX
@article{Lim2024,
  author = {Lim, Chong-Teik and Tay, Shu-Wen and Elangovan, Sakktivel and Ong, Wan-Chee and Lim, Gek-Hsiang and Salazar, Ennaliza and Chan, Webber P W and Tan, Malcolm T K},
  title = {Long‐term effectiveness and persistence rate of ustekinumab dose intensification in a South East Asian inflammatory bowel disease center},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1111/jgh.16562}
}
Kostenlos starten →